The study titled 'Serendipitous COVID-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime' has been uploaded on medRxiv, a preprint server and is yet to be peer reviewed.
In a letter to the principal health secretary of Maharashtra that was also marked to all states and Union Territories (UTs), the Union Health Ministry said this surge is of particular concern from the public health point of view.
iNCOVACC is the world's first intranasal vaccine for COVID-19 to receive approval for the primary two-dose schedule, and as a heterologous booster dose.
Following up first doses of the AstraZeneca or Pfizer vaccines with second doses of the Moderna or Novavax jabs generates robust immune response against COVID-19, according to a study published in The Lancet journal.
'Who are the people who are dying?' 'What is their profile?' 'We need to know these things.' 'We do not take health issues seriously.'
SII has so far provided more than 170 crore doses of Covishield to the government for the national immunisation programme.
A bench of Justices L Nageswara Rao and B R Gavai said bodily autonomy and integrity are protected under Article 21 of the Constitution.
In the major Indian cities, the Omicron variant of the coronavirus is accounting for more than 50 per cent of the fresh cases of the infection and the massive surge in the number of cases over the last one week is indicative of a third wave of the pandemic, as is being witnessed in several countries, Dr N K Arora, chairman of the COVID-19 working group of the NTAGI, said on Tuesday.
The minister will review the COVID-19 situation at 11:30 am on Wednesday 'considering the international scenario', they said.
The study, published in Canadian Medical Association Journal, found that the risk to vaccinated people was lower when unvaccinated mixed with unvaccinated.
Zydus Cadila has agreed to bring down the price of its COVID-19 vaccine to Rs 265 a dose following persistent negotiations by the government but a final deal is yet to be reached, sources said on Sunday.
The gap between second dose of COVID-19 vaccine and the third, which is being called a 'precaution dose,' is likely to be nine to 12 months, official sources said on Sunday.
With the COVID-19 cases under subsidence in the country, the viral infection has risen significantly due to the emergence of a new virus for which the experts are continuously advising to take precautions.
He explained, "Children between the age of 12 and 18 years, particularly those in the age group of 15 to 18 years, are very much like adults. Our research within the country also says that almost two-thirds of the deaths below 18 years which occurred due to COVID in India are within this age group. So, this decision was mainly taken to protect the adolescents."
Serum Institute of India (SII) and Bharat Biotech have also stopped producing the Covishield and Covaxin vaccines respectively.
"We have received feedback that certain immunisation centres are recommending taking three paracetamol 500 mg tablets along with Covaxin for children. No paracetamol or painkillers are recommended after being vaccinated with Covaxin," Bharat Biotech said in a Twitter post.
The modus operandi for immunising the country's 1.35 billion population in stages has been thrashed out in more than one meeting among top government officials in the health ministry and the Prime Minister's Office.
The Centre has started the process of identifying around 30 crore priority beneficiaries who will be given vaccine in the initial phase. The Centre will procure the vaccine directly and make it available free-of-cost for the priority beneficiaries.
Pune-based Serum Institute of India (SII) is sitting on 200 million doses of Covishield that were manufactured in December and are set to expire in September. The company is likely to destroy these vaccines if nothing works out, Sohini Das reports.
Prime Minister Narendra Modi is likely to announce a host of initiatives for the health sector on Independence Day with the highlights being the 'Heal in India' and 'Heal by India' projects and a roadmap to eliminate sickle cell disease by 2047, official sources said.
A dipstick survey covering 30 villages in Rajasthan threw up some worrisome numbers. About 250 children missed their regular vaccination schedule in March alone. These numbers are alarming, since India has around 600,000 villages according to the 2011 census. Sohini Das reports.
The vaccine would not have production scalability issues unlike Covaxin, Bharat Biotech's COVID-19 virus vaccine.
The government cannot be held liable to compensate for the deaths due to an adverse event following immunisation (AEFI) post administration of Covid-19 vaccines, the Centre has told the Supreme Court.
The Union health ministry has reduced the gap between the second and precaution dose of COVID-19 vaccine for all beneficiaries from nine to six months following a recommendation by National Technical Advisory Group on Immunisation (NTAGI).
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of Oxford/AstraZeneca's Covid-19 vaccine, administered in India as Covishield, over feared serious side effects such as heart attack and stroke.
'The protective effect of the vaccine lasts for about nine months to a year.' 'For health workers that period is already over. This is the right time to augment their immunity.'
The decision to increase the gap between two doses of Covishield from 4-6 weeks to 12-16 weeks was based on scientific decision and there was no dissenting voice among the National Technical Advisory Group on Immunisation members.
Speaking at a virtual conference organised by the Confederation of Indian Industry, Suchitra Ella, joint Managing Director of the city-based vaccine maker, said the company's facilities in four cities -- Hyderabad, Bengaluru, Pune and Ankaleshwar -- are currently producing Covaxin.
An important focus of the dry run will be on management of any possible adverse events following immunisation.
The company said it had conducted two separate trials for its intranasal Covid vaccine, one as a primary dose schedule and another as a booster dose, for subjects who have been double vaccinated with the two commonly administered Covid vaccines in India.
The NTAGI has recommended that those who need to travel overseas can take the precaution dose of Covid vaccine as required by the country they are travelling to, before the stipulated nine-month waiting period, sources told PTI.
Amid concerns over dangerous side-effects of the Oxford's COVID-19 vaccine, India is evaluating all serious adverse events post-vaccination to determine the causality aspects of Covishield and Covaxin, an expert associated with the process said on Saturday.
Out of the 447 adverse events following immunisation, only 3 required hospitalisation.
With talks underway between the central government and Zydus Cadila over the pricing of the COVID-19 vaccine ZyCov-D, the pharma company is learnt to have proposed a price of Rs 1,900 for its three-dose jab that can be given to those above 12 years of age.
According to some experts, there is not much difference in the number of seasonal flu cases and that of COVID-19, even though they stressed that surveillance for newer variants should continue in the off chance of a new lineage of coronavirus catching the country off guard.
While there is a continuous increasing trend in COVID-19 cases and deaths globally, particularly in America and Europe and the situation in the world is becoming worrisome, in contrast the scene in India is satisfying as the cases and deaths are declining, Dr V K Paul, member (health) at NITI Aayog, told a press conference.
Zydus Cadila COVID-19 vaccine for children above 12 years is expected to be available by August as its trials are likely to be completed by July-end, said Dr N K Arora, Chairman, National Technical Advisory Group on Immunisation (NTAGI).
As the country eagerly awaits an expected coronavirus vaccination drive in January, at least 125 intended beneficiaries each in four states who had registered on the Co-WIN App were on Monday sent SMSes informing them about the time and place of their 'COVID-19 vaccination' under a mock-drill to administer the shots at designated centres.
The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances